Trial
NCT03640221
Ertugliflozin Versus Hydrochlorothiazide in Reducing Sympathetic Neural Overactivity in Patients With Hypertension and Recently-diagnosed Type 2 Diabetes.
Phase IVWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
Cedars-Sinai Medical Center
Collaborators
Merck Sharp & Dohme LLC
Condition
Hypertension
Intervention
Ertugliflozin
Why stopped
Study withdrawn prior to IRB approval and enrollment
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-01-14